CNSP
vs
S&P 500


Over the past 12 months, CNSP has underperformed S&P 500, delivering a return of -94% compared to the S&P 500's +15% growth.
Stocks Performance
CNSP vs S&P 500
Performance Gap
CNSP vs S&P 500
Performance By Year
CNSP vs S&P 500
CNS Pharmaceuticals Inc
Glance View
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. The firm is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The firm is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The firm is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
